RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $235 to $250.
June 25, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi maintains an Outperform rating on Alnylam Pharmaceuticals and raises the price target from $235 to $250.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term. Investors often view such updates as a strong signal of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100